PMDA posts follow-up notice on proper use of Fiasp injection in insulin pumps
「製薬企業からの適正使用等に関するお知らせ」に「フィアスプ注 インスリンポンプでの適正使用のお願い（続報）」を掲載しました
Published: 2026-06-12 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-06-12, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted a follow-up notice titled 'Request for Proper Use of Fiasp Injection in Insulin Pumps.' The notice appears in PMDA's collection of proper-use communications from pharmaceutical companies.
Business Impact
The notice may be relevant to healthcare professionals and patients using Fiasp injection in insulin pumps because it concerns proper use in that setting; the title does not specify the updated precautions.
Recommended Action
Review of the official Japanese follow-up notice could clarify the proper-use precautions and what has changed from the earlier communication.